相关实验视频
Updated: Jan 13, 2026

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
Published on: April 18, 2025
在临床连续过程中,基于粉样蛋白和陶定子发射断层扫描的阶段的特征
Karly A Cody1, Andrzej Sokołowski1, Emily Johns1
1Department of Neurology and Neurological Sciences, Stanford University, Stanford, California, USA.
粉样蛋白和粉样蛋白的正子发射断层扫描 (PET) 阶段测定在各种队列和标记物中是可行的. 研究结果显示,粉样蛋白和酸负担具有显著的异质性,随着临床疾病严重程度的增加而增加.
科学领域:
- 神经成像是一种神经成像.
- 生物标志物 生物标志物
- 临床神经学 临床神经学
背景情况:
- 在队列和标记物中标准化正电子发射断层扫描 (PET) 数据对于理解神经退行性疾病进展至关重要.
- 粉样蛋白和蛋白PET成像是阿尔茨海默病和相关痴呆症的关键生物标志物.
研究的目的:
- 为了在多个队列和追踪器中标准化PET数据.
- 在临床连续过程中,从认知上不受损害到痴呆症,对粉样蛋白和粉样蛋白PET严重程度的频率进行表征.
主要方法:
- 使用了临床分期 (认知不受损,轻度认知障碍,痴呆症) 和PET成像数据 (粉样细胞,tau Braak分期).
- 使用顺序逻辑回归来估计基于PET的阶段的累积概率.
- 分析了来自10,396个人的粉样蛋白PET和3,295个人的蛋白PET的数据.
主要成果:
- 粉样蛋白水平随着年龄的增长而增加,在认知不受损和轻度认知障碍阶段,并且在痴呆症中最高.
- 的严重程度与粉样蛋白负担和临床阶段相关,具有复杂的年龄关联.
- 在每个临床阶段观察到广泛的粉样蛋白和PET严重程度.
结论:
- 基于PET的分期是一种可行的方法,可以跨越多样化的队列和追踪器.
- 在临床范围内的粉样蛋白和蛋白负担存在显著的异质性.
- 粉样蛋白和粉样蛋白PET严重程度通常随着临床疾病严重程度的增加而增加,粉样蛋白的可能性受到年龄,粉样蛋白和临床状态的影响.
更多相关视频
10:04Imaging Amyloid Tissues Stained with Luminescent Conjugated Oligothiophenes by Hyperspectral Confocal Microscopy and Fluorescence Lifetime Imaging
Published on: October 20, 2017
12:28Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains
Published on: June 3, 2020
相关概念视频
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
Positron Emission Tomography
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...
Imaging Studies II: Positron Emission Tomography and Scintigraphy
Fundamental Principles of PET
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid Fibrils
Alzheimer's Disease: Treatment